Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lerner's UV light therapy for psoriasis gets FDA clearance

This article was originally published in Clinica

Executive Summary

Lerner Medical Devices' Levia, an at-home light therapy device, has received US FDA 510(k) clearance for the treatment of psoriasis. The product uses ultraviolet B (UVB) light to slow the growth of affected skin cells, and is designed to treat psoriasis of the scalp and small flare-ups of the disease. It can also be used in other skin conditions such as vitiligo, which causes depigmentation of patches of skin. The Levia system has delivery attachments, the Lite-Brush and Lite-Spot, which direct the UVB light to affected areas and minimise exposure of healthy skin. Lerner (Los Angeles, California) plans to launch the product this quarter.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT045162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel